TLR3, TICAM1 and human rhinovirus infection

TLR3、TICAM1 与人鼻病毒感染

基本信息

  • 批准号:
    8772186
  • 负责人:
  • 金额:
    $ 22.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): TLR3, TICAM1 and human rhinovirus infection Human rhinovirus (RV) infection is associated with the common cold and asthma development and/or exacerbation. To date, we and others have reported a complex of RV-induced epithelial proinflammatory and antiviral pathways, which involve TLR3, RIG1, MDA5 and PKR. Recently, we have shown that TLR3 activation appears to be upstream of all other pathways, and TLR3 desensitization via TICAM1 degradation is critical to antiviral defense by airway epithelium. To further elucidate the underlying mechanism, we propose to first determine the impact of TLR3 desensitization on epithelial anti-viral defense in vitro. In this study, we will determine the kinetics of TICAM1 protein turnover and its downstream cellular antiviral responses induced by dsRNA or by RV. We will also determine the cellular antiviral status during this process. Lastly, we will overexpress TICAM1 to test if this could restore the cellular antiviral response. To evaluate the potential alteration of TLR3 desensitization in asthma, we will determine whether or not Th2-cytokine- treated epithelial cells have altered desensitization, and whether or not human asthmatic epithelial cells are defective in this process as compared to the normal cells. Then, we propose to determine the mechanistic basis of TICAM1 degradation. In this aim, we will test a novel hypothesis that TICAM1 is degraded via chaperone mediated autophagy. This is a high-risk and high-impact project that is well suited for R21 mechanism. If we succeed, we will be able to gain novel insight into the TLR3-TICAM1 mediated airway antiviral defense and to identify a risk factor for asthma exacerbation.
描述(由申请人提供):TLR 3、TICAM 1和人鼻病毒感染人鼻病毒(RV)感染与普通感冒和哮喘的发展和/或恶化相关。迄今为止,我们和其他人已经报道了一个复杂的RV诱导的上皮促炎和抗病毒途径,其中涉及TLR 3,RIG 1,MDA 5和PKR。最近,我们发现TLR 3激活似乎是所有其他途径的上游,并且通过TICAM 1降解的TLR 3脱敏对于气道上皮的抗病毒防御至关重要。为了进一步阐明潜在的机制,我们建议首先在体外确定TLR 3脱敏对上皮抗病毒防御的影响。在这项研究中,我们将确定TICAM 1蛋白周转的动力学及其下游细胞的抗病毒反应诱导的dsRNA或RV。我们还将在此过程中确定细胞的抗病毒状态。最后,我们将过表达TICAM 1,以测试这是否可以恢复细胞的抗病毒反应。为了评估哮喘中TLR 3脱敏的潜在改变,我们将确定Th 2-细胞因子处理的上皮细胞是否具有改变的脱敏,以及与正常细胞相比,人哮喘上皮细胞在该过程中是否有缺陷。然后,我们建议确定TICAM 1降解的机制基础。在这个目标中,我们将测试一个新的假设,TICAM 1是通过分子伴侣介导的自噬降解。这是一个高风险和高影响的项目,非常适合R21机制。如果我们成功,我们将能够获得新的见解TLR 3-TICAM 1介导的气道抗病毒防御,并确定哮喘急性发作的危险因素。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yin Chen其他文献

Yin Chen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yin Chen', 18)}}的其他基金

Fungal Asthma and Lung Innate Immunity
真菌性哮喘和肺部先天免疫
  • 批准号:
    10386885
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Fungal Asthma and Lung Innate Immunity
真菌性哮喘和肺部先天免疫
  • 批准号:
    10056131
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Fungal Asthma and Lung Innate Immunity
真菌性哮喘和肺部先天免疫
  • 批准号:
    10160785
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Fungal Asthma and Lung Innate Immunity
真菌性哮喘和肺部先天免疫
  • 批准号:
    10613928
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Arsenic exposure, CC16 and its effect on pulmonary function
砷暴露、CC16及其对肺功能的影响
  • 批准号:
    9308642
  • 财政年份:
    2017
  • 资助金额:
    $ 22.73万
  • 项目类别:
Arsenic exposure, CC16 and its effect on pulmonary function
砷暴露、CC16及其对肺功能的影响
  • 批准号:
    9892007
  • 财政年份:
    2017
  • 资助金额:
    $ 22.73万
  • 项目类别:
Environmental Health Sciences: Transformational Research Undergraduate Experience (E-H-TRUE)
环境健康科学:变革性研究本科经历(E-H-TRUE)
  • 批准号:
    10208884
  • 财政年份:
    2015
  • 资助金额:
    $ 22.73万
  • 项目类别:
Environmental Health Sciences: Transformational Research Undergraduate Experience (E-H-TRUE)
环境健康科学:变革性研究本科经历(E-H-TRUE)
  • 批准号:
    10612407
  • 财政年份:
    2015
  • 资助金额:
    $ 22.73万
  • 项目类别:
Environmental Health Sciences: Transformational Research Undergraduate Experience (E-H-TRUE)
环境健康科学:变革性研究本科经历(E-H-TRUE)
  • 批准号:
    10401934
  • 财政年份:
    2015
  • 资助金额:
    $ 22.73万
  • 项目类别:
Environmental Health Sciences: Transformational Research Undergraduate Experience (E-H-TRUE)
环境健康科学:变革性研究本科经历(E-H-TRUE)
  • 批准号:
    10004913
  • 财政年份:
    2015
  • 资助金额:
    $ 22.73万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 22.73万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 22.73万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 22.73万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 22.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了